Evidence map›Paper›PMID 26910538›Full record

SynthesisPLoS genetics2016

Six Novel Loci Associated with Circulating VEGF Levels Identified by a Meta-analysis of Genome-Wide Association Studies.

Seung Hoan Choi, Daniela Ruggiero, Rossella Sorice, Ci Song, Teresa Nutile, Albert Vernon Smith, Maria Pina Concas, Michela Traglia, Caterina Barbieri, Ndeye Coumba Ndiaye and 22 more

Open access · goldAbstract readMeta-Analysis
In one paragraph

Synthesis in PLoS genetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
7.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it, 82 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. New perspectives on VEGF signalling in Alzheimer's disease.Brain pathology (Zurich, Switzerland) · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. VEGF-A related SNPs: a cardiovascular context.Frontiers in cardiovascular medicine · 2023
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 17 institutions in 7 countries.

Seung Hoan ChoiDepartment of Neurology, Boston University School of Medicine, Boston, Massachusetts, United States of America.
Daniela RuggieroInstitute of Genetics and Biophysics, National Research Council of Italy, Naples, Italy.
Rossella SoriceInstitute of Genetics and Biophysics, National Research Council of Italy, Naples, Italy.
Ci SongPopulation Sciences Branch, National Heart, Lung and Blood Institute's Framingham Heart Study, Framingham, Massachusetts, United States of America.
Teresa NutileInstitute of Genetics and Biophysics, National Research Council of Italy, Naples, Italy.
Albert Vernon SmithIcelandic Heart Association, Kopavogur, Iceland.
Maria Pina ConcasInstitute of Population Genetics, National Research Council of Italy, Sassari, Italy.
Michela TragliaDivision of Genetics and Cell Biology, San Raffaele Scientific Institute, Milano, Italy.
Caterina BarbieriDivision of Genetics and Cell Biology, San Raffaele Scientific Institute, Milano, Italy.
Ndeye Coumba NdiayeUMR INSERM U1122, IGE-PCV "Interactions Gène-Environnement en Physiopathologie Cardio-Vasculaire", Faculté de Pharmacie, Université de Lorraine, Nancy, France.
Maria G StathopoulouUMR INSERM U1122, IGE-PCV "Interactions Gène-Environnement en Physiopathologie Cardio-Vasculaire", Faculté de Pharmacie, Université de Lorraine, Nancy, France.
Vasiliki LagouWellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.
Giovanni Battista MaestraleInstitute of Population Genetics, National Research Council of Italy, Sassari, Italy.
Cinzia SalaDivision of Genetics and Cell Biology, San Raffaele Scientific Institute, Milano, Italy.
Stephanie DebetteDepartment of Neurology, Boston University School of Medicine, Boston, Massachusetts, United States of America.
Peter KovacsUniversity of Leipzig, IFB Adiposity Diseases, Leipzig, Germany.
Lars LindDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
John LamontRandox Laboratories, Crumlin, United Kingdom.
Peter FitzgeraldRandox Laboratories, Crumlin, United Kingdom.
Anke TönjesUniversity of Leipzig, Department of Medicine, Leipzig, Germany.
Vilmundur GudnasonIcelandic Heart Association, Kopavogur, Iceland.
Daniela TonioloDivision of Genetics and Cell Biology, San Raffaele Scientific Institute, Milano, Italy.
Mario PirastuInstitute of Population Genetics, National Research Council of Italy, Sassari, Italy.
Celine BellenguezInstitut Pasteur de Lille, Lille, France.
Ramachandran S VasanNational Heart, Lung and Blood Institute's Framingham Heart Study, Framingham, Massachusetts, United States of America.
Erik IngelssonDepartment of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Anne-Louise LeuteneggerINSERM U946, Paris, France.
Andrew D JohnsonPopulation Sciences Branch, National Heart, Lung and Blood Institute's Framingham Heart Study, Framingham, Massachusetts, United States of America.
Anita L DeStefanoDepartment of Neurology, Boston University School of Medicine, Boston, Massachusetts, United States of America.
Sophie Visvikis-SiestUMR INSERM U1122, IGE-PCV "Interactions Gène-Environnement en Physiopathologie Cardio-Vasculaire", Faculté de Pharmacie, Université de Lorraine, Nancy, France.
Sudha SeshadriDepartment of Neurology, Boston University School of Medicine, Boston, Massachusetts, United States of America.
Marina CiulloInstitute of Genetics and Biophysics, National Research Council of Italy, Naples, Italy.
National Research Council · ITBoston University · USInserm · FRInstitute of Genetics and Biophysics · ITRandox (United Kingdom) · GBScience for Life Laboratory · SEFramingham Heart Study · USIcelandic Heart Association · ISIFB Adiposity Diseases · DELeipzig University · DENational Heart Lung and Blood Institute · USSorbonne Paris Cité · FRUniversité de Lorraine · FRUniversité Lille Nord de France · FRUniversity of Iceland · ISUniversity of Oxford · GBUppsala University · SE

Funding

Neuropathology CoreP30AG013846 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI KOWALL, NEIL W. · 1996 to 2020
$29.1M
UC Davis Alzheimer's Disease Core CenterP30AG010129 · NIA · UNIVERSITY OF CALIFORNIA DAVIS · PI JOHNSON, DAVID K · 1991 to 2020
$28.3M
Cardiovascular Genomics and Bioinformatics projectsZIAHL006170 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI JOHNSON, ANDREW · 2013 to 2025
$25.3M
PRECURSORS OF STROKE INCIDENCE AND PROGNOSISR01NS017950 · NINDS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Hugo Javier Aparicio, Jose Rafael Romero · 1985 to 2026
$22.9M
EPIDEMIOLOGY OF DEMENTIA IN THE FRAMINGHAM STUDYR01AG008122 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI AU, RHODA, SESHADRI, SUDHA · 1989 to 2015
$14.4M
MRI, Cognitive, Genetic & Biomarker Precursors of AD & Dementia in Young AdultsR01AG033040 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI AU, RHODA, SESHADRI, SUDHA · 2009 to 2019
$11.2M
Collaborative GWAS of Dementia, AD and related MRI and Cognitive EndophenotypesR01AG033193 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI SESHADRI, SUDHA · 2009 to 2016
$4.4M
CHARGE: Identifying Risk & Protective SNV for AD in ADSP Case-control SampleU01AG049505 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI SESHADRI, SUDHA · 2014 to 2017
$3.0M
A Genome-Wide Association Study of Ischemic Brain Vascular InjuryR01HL093029 · NHLBI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI FORNAGE, MYRIAM · 2009 to 2010
$1.6M
Neurotrophic Factors: Genetic Variation and Serum Levels in Brain AgingR01AG031287 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI SESHADRI, SUDHA · 2009 to 2010
$1.2M
ASYMPTOMATIC LEFT VENTRICULAR DYSFUNCTIONK24HL004334 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI RAMACHANDRAN, VASAN S · 2001 to 2008
$707k
THE FRAMINGHAM HEART STUDY-N01HC25195-268025195-268025195N01HC025195 · HC · TRUSTEES OF BOSTON UNIVERSITY · PI WOLF, PHILIP A · 2002 to 2006
–
NHLBI NIH HHS HL-077477NHLBI NIH HHS HL093029NHLBI NIH HHS HL-K24-04334NHLBI NIH HHS N01 HC025195NHLBI NIH HHS N01-HC-25195NHLBI NIH HHS R01 HL077477NHLBI NIH HHS R01 HL093029NIA NIH HHS AG031287NIA NIH HHS AG033040NIA NIH HHS AG033193NIA NIH HHS AG08122NIA NIH HHS N01 AG012100NIA NIH HHS N01-AG012100NIA NIH HHS P30 AG010129NIA NIH HHS P30 AG013846NIA NIH HHS P30AG013846NIA NIH HHS R01 AG008122NIA NIH HHS R01 AG031287NIA NIH HHS R01 AG033040NIA NIH HHS R01 AG033193NIA NIH HHS U01 AG049505NINDS NIH HHS NS17950NINDS NIH HHS R01 NS017950PHS HHS U0149505
6 · The paper itself

Abstract

Vascular endothelial growth factor (VEGF) is an angiogenic and neurotrophic factor, secreted by endothelial cells, known to impact various physiological and disease processes from cancer to cardiovascular disease and to be pharmacologically modifiable. We sought to identify novel loci associated with circulating VEGF levels through a genome-wide association meta-analysis combining data from European-ancestry individuals and using a dense variant map from 1000 genomes imputation panel. Six discovery cohorts including 13,312 samples were analyzed, followed by in-silico and de-novo replication studies including an additional 2,800 individuals. A total of 10 genome-wide significant variants were identified at 7 loci. Four were novel loci (5q14.3, 10q21.3, 16q24.2 and 18q22.3) and the leading variants at these loci were rs114694170 (MEF2C, P = 6.79 x 10(-13)), rs74506613 (JMJD1C, P = 1.17 x 10(-19)), rs4782371 (ZFPM1, P = 1.59 x 10(-9)) and rs2639990 (ZADH2, P = 1.72 x 10(-8)), respectively. We also identified two new independent variants (rs34528081, VEGFA, P = 1.52 x 10(-18); rs7043199, VLDLR-AS1, P = 5.12 x 10(-14)) at the 3 previously identified loci and strengthened the evidence for the four previously identified SNPs (rs6921438, LOC100132354, P = 7.39 x 10(-1467); rs1740073, C6orf223, P = 2.34 x 10(-17); rs6993770, ZFPM2, P = 2.44 x 10(-60); rs2375981, KCNV2, P = 1.48 x 10(-100)). These variants collectively explained up to 52% of the VEGF phenotypic variance. We explored biological links between genes in the associated loci using Ingenuity Pathway Analysis that emphasized their roles in embryonic development and function. Gene set enrichment analysis identified the ERK5 pathway as enriched in genes containing VEGF associated variants. eQTL analysis showed, in three of the identified regions, variants acting as both cis and trans eQTLs for multiple genes. Most of these genes, as well as some of those in the associated loci, were involved in platelet biogenesis and functionality, suggesting the importance of this process in regulation of VEGF levels. This work also provided new insights into the involvement of genes implicated in various angiogenesis related pathologies in determining circulating VEGF levels. The understanding of the molecular mechanisms by which the identified genes affect circulating VEGF levels could be important in the development of novel VEGF-related therapies for such diseases.

Indexed as

Genetic LociChromosomes, HumanGene ExpressionGenome-Wide Association StudyHumansPolymorphism, Single NucleotideVascular Endothelial Growth Factor AWhite PeopleVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID26910538
PMCPMC4766012
OpenAlexW2276479479

What Socratic holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.